PPARG and cancer: Rosiglitazone downregulates PI3K as it belongs to thiazolidinedione class of drugs which are potentially useful in treating several cancers (Ramos-Nino and Littenberg, 2008) through both PPARγ-dependent and PPARγ-independent mechanisms.